Press Releases

July 21, 2022
Newly Issued European Patent Broadens IN8bio’s Drug Resistant Immunotherapy (DRI) Platform
PDF Version
July 12, 2022
IN8bio Appoints Kenneth R. LaMontagne, Ph.D., to Lead Business Development
PDF Version
June 30, 2022
IN8bio to Present at July Investor and Scientific Conferences
PDF Version
June 8, 2022
IN8bio Announces Presentation at Jefferies Global Healthcare Conference and Additional June Investor and Scientific Conferences
PDF Version
June 6, 2022
IN8bio Announces Positive Glioblastoma Multiforme (GBM) Clinical Updates from the INB-200 Phase 1 Trial Presented at ASCO 2022
PDF Version